Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd. squib

Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30% royalties on future salesTeva will receive an exclusive license to bring firibastat to its home market, Israel PARIS, Nov. 25, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat difficult-to-treat/resistant hypertension, has today announced the signing of an exclusive
Continue reading on Yahoo! Sports...